Suven Life Sciences Limited (BOM:530239)

Market Cap	41.18B
Revenue (ttm)	75.74M
Net Income (ttm)	-1.43B
Shares Out	218.07M
EPS (ttm)	-6.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	473,785
Average Volume	103,334
Open	155.90
Previous Close	152.80
Day's Range	154.60 - 175.00
52-Week Range	83.27 - 175.00
Beta	0.64
RSI	80.83
Earnings Date	May 28, 2025

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1989
• Employees: 141
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530239

Financial Performance

In 2023, Suven Life Sciences's revenue was 116.93 million, a decrease of -13.99% compared to the previous year's 135.95 million. Losses were -1.05 billion, -11.15% less than in 2022.